ALMS

Alumis Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website alumis.com
Employees(FY) 107
ISIN US0223071020

Performance

+1.03%

-14.78%

-22.43%

-33.68%

YTD

-33.68%

Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Advanced Technical Analysis

Stock Analysis of ALMS

Stock Rank

Recent News & Updates

2024-12-18 19:00
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005(Globenewswire)
2024-11-14 16:05
Alumis Presents Data Highlighting ESK-001â€™s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024(GlobeNewswire)
2024-11-14 03:05
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024(Globenewswire)
2024-11-13 16:05
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements(GlobeNewswire)
2024-11-13 03:05
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements(Globenewswire)
2024-11-04 08:00
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference(GlobeNewswire)
2024-11-03 19:00
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference(Globenewswire)
2024-09-27 09:00
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study(GlobeNewswire)
2024-09-26 21:00
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study(Globenewswire)
2024-09-03 16:29
Alumis to Participate in Upcoming September Investor Conferences(GlobeNewswire)
2024-09-03 04:29
Alumis to Participate in Upcoming September Investor Conferences(Globenewswire)
2024-08-13 16:05
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements(GlobeNewswire)
2024-08-13 04:05
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements(Globenewswire)
2024-07-29 08:00
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis(GlobeNewswire)
2024-07-28 20:00
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis(Globenewswire)
2024-06-27 23:57
Alumis Announces Pricing of Initial Public Offering(GlobeNewswire)
2024-06-27 11:57
Alumis Announces Pricing of Initial Public Offering(Globenewswire)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.